Tus Pharmaceutical Group Co Ltd banner
T

Tus Pharmaceutical Group Co Ltd
SZSE:000590

Watchlist Manager
Tus Pharmaceutical Group Co Ltd
SZSE:000590
Watchlist
Price: 11.12 CNY 0.18% Market Closed
Market Cap: ¥2.7B

Balance Sheet

Balance Sheet Decomposition
Tus Pharmaceutical Group Co Ltd

Balance Sheet
Tus Pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024 Dec-2025
Assets
Cash & Cash Equivalents
41
11
18
39
23
25
16
14
9
28
159
66
48
56
123
124
321
314
343
246
235
178
161
170
Cash
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
246
235
178
161
170
Cash Equivalents
41
11
18
39
23
25
16
14
9
28
159
66
48
56
123
124
321
314
343
0
0
0
0
0
Short-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
193
0
0
0
75
25
0
0
0
Total Receivables
195
220
239
226
297
205
175
119
130
105
151
107
143
112
94
140
66
126
113
131
147
215
194
87
Accounts Receivables
166
182
187
183
250
122
112
63
43
37
30
28
11
12
4
16
17
6
2
0
24
22
8
2
Other Receivables
29
39
52
42
47
82
63
57
87
68
122
80
133
100
90
125
50
120
111
131
123
193
186
85
Inventory
121
110
92
83
37
55
77
63
86
88
70
64
42
69
67
63
69
51
51
87
118
130
125
110
Other Current Assets
13
10
10
10
7
13
7
8
11
9
10
43
22
1
1
1
30
1
2
15
4
16
21
12
Total Current Assets
371
351
358
357
363
297
275
204
235
229
391
280
255
239
284
522
487
492
509
554
529
540
500
379
PP&E Net
254
219
212
215
130
128
130
135
154
178
179
122
170
154
159
165
171
201
225
241
290
294
313
312
PP&E Gross
254
219
212
215
130
128
130
135
154
178
179
122
170
154
159
165
171
201
225
241
290
294
313
312
Accumulated Depreciation
107
119
134
148
102
92
97
96
104
114
126
179
102
112
119
122
138
147
159
170
193
209
219
239
Intangible Assets
92
76
67
57
16
85
142
139
137
134
132
146
156
191
172
168
138
135
138
134
157
132
131
123
Goodwill
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
0
0
0
0
0
137
132
13
0
Note Receivable
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
5
3
2
Long-Term Investments
6
37
38
35
42
30
30
35
41
60
3
3
1
0
0
15
15
15
14
32
36
40
38
51
Other Long-Term Assets
2
1
1
1
11
8
9
3
2
1
1
1
5
4
8
4
6
5
6
7
10
9
16
22
Other Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
0
0
0
0
0
137
132
13
0
Total Assets
725
N/A
685
-5%
677
-1%
665
-2%
562
-15%
549
-2%
586
+7%
516
-12%
569
+10%
603
+6%
704
+17%
553
-22%
587
+6%
587
+0%
631
+7%
874
+39%
817
-7%
847
+4%
892
+5%
968
+8%
1 167
+21%
1 151
-1%
1 013
-12%
889
-12%
Liabilities
Accounts Payable
91
79
78
64
48
47
62
68
78
73
83
86
46
42
42
44
27
35
32
32
50
84
73
64
Accrued Liabilities
52
35
37
44
34
24
52
53
60
50
11
18
32
33
26
33
23
31
35
46
51
47
48
42
Short-Term Debt
251
261
239
232
160
124
106
101
58
63
0
0
78
64
113
38
52
36
47
42
66
32
36
28
Current Portion of Long-Term Debt
0
0
4
0
0
0
0
4
10
0
0
0
0
0
0
0
0
0
0
3
13
12
14
21
Other Current Liabilities
29
31
36
39
26
39
34
47
81
63
122
140
162
127
74
49
40
52
48
65
92
75
65
46
Total Current Liabilities
422
406
394
381
267
234
253
273
287
249
216
244
318
265
255
165
141
154
161
187
271
249
236
201
Long-Term Debt
22
20
16
16
0
0
14
10
0
0
0
0
0
0
0
20
20
0
0
6
95
83
84
51
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
6
5
6
Minority Interest
3
1
0
1
0
0
0
1
0
0
0
0
0
0
3
0
0
0
0
2
4
4
3
2
Other Liabilities
0
0
0
0
8
8
0
3
3
3
10
39
84
117
112
106
76
71
86
93
90
85
87
82
Total Liabilities
441
N/A
427
-3%
409
-4%
395
-3%
275
-30%
241
-12%
267
+11%
285
+6%
290
+2%
252
-13%
225
-10%
283
+26%
403
+42%
382
-5%
370
-3%
290
-21%
237
-18%
225
-5%
247
+10%
288
+16%
469
+63%
427
-9%
415
-3%
342
-18%
Equity
Common Stock
203
203
203
203
203
203
203
203
203
203
223
223
223
223
223
240
240
240
240
239
239
239
239
239
Retained Earnings
32
59
53
49
36
15
1
86
39
33
103
107
192
170
115
96
134
91
69
33
15
10
115
166
Additional Paid In Capital
121
121
118
118
120
119
115
115
115
115
153
152
152
152
152
440
474
474
474
474
474
474
474
474
Unrealized Security Profit/Loss
9
7
1
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Equity
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
Total Equity
283
N/A
259
-9%
268
+3%
269
+1%
287
+7%
307
+7%
319
+4%
232
-27%
279
+20%
351
+26%
479
+36%
270
-44%
184
-32%
206
+12%
261
+27%
583
+123%
580
-1%
622
+7%
645
+4%
680
+5%
698
+3%
724
+4%
598
-17%
548
-8%
Total Liabilities & Equity
725
N/A
685
-5%
677
-1%
665
-2%
562
-15%
549
-2%
586
+7%
516
-12%
569
+10%
603
+6%
704
+17%
553
-22%
587
+6%
587
+0%
631
+7%
874
+39%
817
-7%
847
+4%
892
+5%
968
+8%
1 167
+21%
1 151
-1%
1 013
-12%
889
-12%
Shares Outstanding
Common Shares Outstanding
223
223
223
223
223
223
223
223
223
223
223
223
223
223
223
240
240
240
240
239
239
239
239
239
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett